Yinghe Neuroscience Completes Over RMB 100 Million Angel Financing to Accelerate Innovative Neurotechnology Medical Device Development

VCBeat (WeChat: vcbeat) learned that recently, AMYGDALA NEURO completed an angel round of financing exceeding 100 million yuan. This round of financing was jointly led by Shenzhen Qianhai Bangqin Investment Co., Ltd. ("Bangqin Capital") and Lilly Asia Ventures ("LAV"). Listed company Shenzhen New Industries Biomedical Engineering Co., Ltd. ("New Industries Bio"), Xijiao 1896 Science and Innovation Fund, and several other institutions followed the investment, with the original shareholder of Yingmai Medical continuing to increase their stake. DeepSnow Capital served as the financial advisor for the company in this financing transaction.

AMYGDALA NEURO, based in China and oriented globally, focuses on developing next-generation neuromodulation and brain-computer interface technologies and products driven by clinical needs. Multiple products under research are aligned with cutting-edge global innovative technologies, achieving technological breakthroughs and filling industrial gaps. To date, the R&D team has overcome technical barriers in autonomous system design, electrode design, chip design, signal acquisition and decoding, algorithm development, and MRI compatibility. A universal neuromodulation platform incorporating some of the most advanced technologies available globally has been established. Several domestically pioneering products under research are about to enter the animal testing and clinical trial stages.

Dr. Ruilin Zhao, CEO of AMYGDALA NEURO, graduated from the Young Talent Class of Xi'an Jiaotong University, obtained a master’s degree in Electrical Engineering and Computer Science with a focus on Artificial Intelligence from MIT, and a Ph.D. in Biomedical Engineering and Medical Physics jointly offered by Harvard and MIT, specializing in brain neuroscience research. Dr. Xiaoyi Min, CTO of the company, graduated from Sichuan University and holds a Ph.D. from Michigan State University, with over 30 years of experience in the research and development of neuromodulation and cardiac rhythm management products at the U.S. headquarters of Medtronic and Abbott, holding more than 160 patents. The core R&D team of the company consists of more than 30 members, spanning multiple disciplines including mechanics, electronics, software, chips, systems, and scientists. Core technical personnel possess extensive experience and technical problem-solving capabilities in the field of active medical devices.

AMYGDALA NEURO CEO Dr. Ruilin ZhaoAMYGDALA NEURO: We deeply appreciate the trust and support from our investors. In recent years, with the launch of large-scale brain science initiatives by China, the United States, Europe, Japan, and other countries, brain science has entered a golden age. Scientists and entrepreneurs worldwide are making great efforts in this field. AMYGDALA NEURO is committed to developing technologies for neural signal detection, sensing, computation, and stimulation, overcoming key technical bottlenecks in brain science, and promoting the domestic production of cutting-edge brain science technologies. With high-quality "Made in China" innovations, we aim to serve a vast number of clinical patients both domestically and internationally. This round of financing will further advance the development and clinical trials of the company’s core products. In the future, AMYGDALA NEURO will continue to increase investment in independent research and development and technology, accelerating the application of innovative brain science medical devices to benefit patients globally.

Dr. Mingyu Liu, General Manager of Bangqin CapitalRepresentation: Brain science and brain-inspired intelligence are key areas in Shenzhen's "20+8" industrial development strategy, and they are also a significant focus for Bangqin. In particular, the two subfields of brain diseases and brain rehabilitation have high clinical efficacy and accessibility. In recent years, advancements in new technologies and materials have driven the expansion of clinical applications in these two directions. We highly value the solid theoretical foundation and extensive practical experience of the AMYGDALA NEURO team in the field of neuromodulation. We also believe that the robust industrial and talent chains of the Greater Bay Area in Shenzhen, along with the top-tier business environment in Pingshan District, will provide immense support to the company.

Applied Medical Technology (Shanghai) Co., Ltd. is an international and forward-thinking innovative Chinese medical device platform company. Gathering like-minded individuals, fostering mutual learning among colleagues and friends, Applied Medical attracts overseas returnees and top domestic talents in the industry. By combining independent research and development with the introduction of overseas technologies, and driven by technological innovation as its core, the company produces high-quality products, builds brand reputation, integrates into China's "Made in China" strategic plan, focuses on China while facing the world, and continuously serves human health based on clinical needs. AMYGDALA NEURO was spun off from Applied Medical.

Bond Capital was founded in 2016 as a rapidly growing emerging fund company, specializing in investing in enterprises within the life and health sector. With a highly focused and in-depth approach, Bond Capital has successfully initiated nearly 10 funds as a fund manager within less than five years of its establishment, incubating and investing in nearly 50 enterprises. These investments span across fields such as medical devices, in vitro diagnostics, pharmaceuticals, and medical services. The core team members come from well-known medical companies like Mindray, Lepu Medical, Haiwang Group, and 3SBio, with extensive experience in both the healthcare industry and venture capital. They possess profound professional backgrounds, rich hands-on expertise, and strong technical comprehension and market analysis abilities. Currently, Bond Capital’s private equity fund management brand is gaining influence, having received funding from Shenzhen Angel Mother Fund, Shenzhen Pingshan Guiding Fund, and several listed companies and renowned enterprises.

Lilly Asia Ventures (LAV) is a premier venture capital firm focused on investments in the life sciences and healthcare industries. Headquartered in Shanghai, China, with offices in Hong Kong, China, and Silicon Valley, USA. Our long-term vision is to build great companies that create breakthrough products to conquer diseases and improve human health, and to be a trusted partner for outstanding entrepreneurs seeking smart capital.

New Industries Biomedical (Stock Code: 300832), established in 1995, has a registered capital of 786.66 million RMB and more than 2,000 employees, over 66% of whom hold a bachelor’s degree or higher. It is a national high-tech enterprise specializing in the research, development, production, sales, and service of in vitro diagnostic products. It is also the first Chinese manufacturer of chemiluminescence products to gain access through the U.S. Food and Drug Administration (FDA). The company's product technology spans numerous disciplines, including clinical medicine, biomedical engineering, medical laboratory science, microelectronics, mechanical design and manufacturing, computer science, and software technology. Its products are mainly used to provide diagnostic information for disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation, and prediction of genetic diseases, earning it the reputation as "the doctor's eyes." The company belongs to the medical device industry, with marketing and service networks covering all provinces and regions in China. Its products are exported to 145 countries and regions overseas, establishing the company as a leader in China’s chemiluminescence immunoassay diagnostics field.

With the strong support of Xi'an Jiaotong University, the Alumni Association of Xi'an Jiaotong University organized multiple renowned alumni entrepreneurs to jointly invest and establish Xijiao 1896 Holdings Group. Xijiao 1896 unites industrial and capital forces represented by the alumni entrepreneur community of the university, relying on the scientific research and talent resources of Xi'an Jiaotong University and other universities, as well as favorable local policies and other advantageous resources. Through high-tech project incubation, equity investment, and deep industry collaboration, it practices an innovative development model of "university + alumni" and "professors + entrepreneurs + engineers." It is committed to building a first-class innovation platform in China that promotes the integration of the two chains (industry and innovation) and has international influence. To facilitate the commercialization of Xi’an Jiaotong University’s technological achievements and support innovation and entrepreneurship among faculty, students, and the broader alumni community, Xijiao 1896 initiated the establishment of a venture capital fund—Xi’an Xijiao 1896 Sci-Tech Investment Partnership (Limited Partnership). By deeply cultivating the university's and alumni’s technological resources, providing in-depth incubation for technology enterprises, and offering post-investment empowerment such as financing services, market promotion, team building, and achievement transformation, it aims to boost innovation and entrepreneurship in science and technology for the university's faculty, students, and alumni.